Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 4

EAGLE PH Form 4 May 02, 20	ARMACEUTICA	ALS, INC.								
FORM	ЛΔ									
FORM 4 UNITED STATES SECURITIES AND EX Washington, D.C. 20							E COMMISSION	OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction See Instruction See Instruction See Instruction Section 16. Form 4 or Form 5 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								January 31, Expires: 2005 Estimated average burden hours per response 0.5		
<i>See</i> Inst 1(b).	ruction	50(II) (of the fi	ivestillent	Compan	IY ACT OF	1940			
(Print or Type	Responses)									
RATOFF STEVEN B Sym EAG			Symbol	er Name and E PHARM EGRX]		-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3. Date (Month			3. Date of	of Earliest Tr Day/Year)	ransaction		X Director Officer (give below)	Officer (give title Other (specify		
Filed(Mo			endment, Da onth/Day/Yea	-	1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
WOODCL	IFF LAKE, NJ 07	6//					Person			
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	lly Owned	
1.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, i any (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Do	port on a separate line	for each also	ss of sea	Code V		(D) Price				
Rennuer. Re	port on a separate fill	Tor cach cla	35 01 500	undes beller	iciality Owl	neu uncenty	or maneetry.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. I Der Sec (In
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 12.67	04/08/2014		A	4,680		<u>(1)</u>	04/07/2024	Common Stock	4,680	

Edgar Filing: EAGLE PHARMACEUTICALS, INC. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
RATOFF STEVEN B C/O EAGLE PHARMACEUTICALS 50 TICE BLVD., SUITE 315 WOODCLIFF LAKE, NJ 07677	, INC.	Х					
Signatures							
/s/ Scott Tarriff, Attorney-in-Fact	04/24/	2014					
**Signature of Reporting Person	Date	•					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option fully vests on April 8, 2015, subject to the reporting person's continuous service with the issuer as of the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.